Sign in / Join Now
ETFs & Funds
Don't know why FDA denied POSIDUR? It is almost exactly like Pacira's EXPAREL. Now strong buying opportunity!
FDA wants another clinical study to verify safety for labeled uses, this is not unusual for the FDA. Just delays approval
That's just great. Now I have to wait another two years until this takes off!
Add a reply...
Latest StockTalks »
people get DRRX breaking news and analysis by email alert.
Get email alerts on DRRX »
Get latest price
From other sites
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection
at TheStreet (Mon, 3:21PM)
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
at TheStreet (Mon, 7:05AM)
Interesting DRRX Call Options For April 2017
at TheStreet (Aug 22, 2016)
DURECT Corporation: Near-Term Approval Likely for REMOXY
at Investopedia (Jul 5, 2016)
The Wall Street Journal: Pfizer ends agreement to develop Remoxy
at MarketWatch.com (Oct 27, 2014)